# New clinical trial map launched in the EU

3 March 2025

Patients can locate trials for potential enrolment in their area.

## Main Content

A new clinical trial map is now accessible from the public website of the  (CTIS). The map is designed to provide patients and healthcare professionals with easy access to comprehensive, real-time information about clinical trials conducted in their area, increasing access to clinical research in the European Union (EU).

Building on the public information contained in CTIS, the map improves how people use the system and find information about clinical trials conducted in Europe. Users can look for ongoing trials by geographic area and medical condition. The search supports queries in lay language and includes an autocorrect system that provides suggestions in case of misspellings. Search results offer investigator’s contact details, enabling members of the public to directly enquire about potential enrolment into a given trial. The first version of the map is provided in English. Additional EU languages will be added in future releases.

The creation of the map is an action of the  (ACT EU) initiative  for 2025-2026. It responds to  for a simple, patient-friendly dashboard for CTIS to help stakeholders, particularly patients, locate clinical trials of interest in Europe. EMA is hosting a public  on 7 March 2025 to provide a live demonstration on how to use all the features. A recording of the session will be available for future reference.

CTIS includes a  for healthcare professionals, patients, and citizens to deliver the high level of transparency foreseen by the . The authorisation and oversight of clinical trials is the responsibility of EU/EEA Member States while EMA is responsible for maintaining CTIS. The European Commission oversees the implementation of the Clinical Trials Regulation.

## Related Content

- 
- 
- 
- 
- 

## External Links

- 
- 
- 
- 
- 
- 
- 

## Contact Point

**Media enquiries**

- Tel. +31 (0)88 781 8427
- E-mail: 

**All other enquiries**

Please submit your request via the 

**Follow us** on 

## Share this Page

- 
- 
- 
- 
- 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
```